With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular space, peptide therapeutics were firmly back on the map as the next modality disrupting drug discovery and development.

This included exploring peptide structure prediction using AI/ML technologies, designing orally bioavailable and cell membrane-permeable peptides using structure-based molecular design, harnessing mRNA display and DNA-encoded libraries for peptide discovery, optimizing peptide synthesis, integrating formulation considerations at the discovery stage, and investigating peptides as drug delivery vehicles.

The 2nd Peptide-Based Therapeutics Summit returned to Boston as your most comprehensive, industry-dedicated forum for overcoming the unique drug discovery challenges of peptide-based therapeutics and powering up your development pipelines to achieve 2025/26 milestones.

As this revitalized space reached a critical tipping point, our delegates were part of the conversation on how advancements in computational, medicinal chemistry, and formulation technologies were driving peptide pipeline progression from hit to lead.

This was your pulse-check opportunity to stay abreast of peptide drug discovery news, build meaningful partnerships, and supercharge cutting-edge peptide-based therapies from concept to clinic and beyond!